Fade Upon TOF Stimulation Induced by Succinylcholine
Muscle Relaxants
About this trial
This is an interventional other trial for Muscle Relaxants focused on measuring succinylcholine, depolarizing muscle relaxants, pharmacologic effects
Eligibility Criteria
Inclusion Criteria:
- ASA PS I or II,
- 18-60 years of age of either sex,
- with a BMI<25Kg/m2
Exclusion Criteria:
- presence of any disease involving the neuromuscular system.
- Presence of any neurologic illness eg . Paraplegia or hemiplegia, spinal cord injuries, stroke, multiple sclerosis.
- No liver or kidney disease.
- Known allergy to succinylcholine.
- Family history of malignant hyperthermia.
- Known pseudocholinesterase deficiency.
- Any skin burns within the last 1 year.
We would also exclude subjects with;
- Central core disease,
- duchenne or Becker muscular dystrophy,
- osteogenesis imperfecta,
- Noonan syndrome,
- arthrogryposis multiplex,
- congenital,
- myotonia,
- neuroleptic malignant syndrome,
- multiminicore disease,
- King Denborough syndrome,
- Native American myopathy,
- hypokalemic periodic paralysis or
- a history of rhabdomyolysis.
We would also exclude any subject with a history of cardiac arrhythmias.
Sites / Locations
- University of Toledo, Health Science Campus
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Experimental
01 mg/kg
0.15 mg/kg
0.2 mg/kg
0.25 mg/kg
0.3 mg/kg
Succinylcholine 0.1 mg/kg will be administered and TOF ratio measured before and after the administration until stable
Succinylcholine 0.15 mg/kg will be administered and TOF ratio measured before and after the administration until stable
Succinylcholine 0.2 mg/kg will be administered and TOF ratio measured before and after the administration until stable
Succinylcholine 0.25 mg/kg will be administered and TOF ratio measured before and after the administration until stable
Succinylcholine 0.3 mg/kg will be administered and TOF ratio measured before and after the administration until stable